Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis

Psychoneuroendocrinology

Volumn 72, Issue , 2016, Pages 1-10

  Miura, Itaru ^a,b   Zhang, Jian Ping ^a,c,d   Hagi, Katsuhiko ^a,e   Lencz, Todd ^a,c,d,f   Kane, John M ^a,c,d,f   Yabe, Hirooki ^b   Malhotra, Anil K ^a,c,d,f   Correll, Christoph U ^a,c,d,f  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotics; DRD2; Hyperprolactinemia; Meta analysis; Prolactin; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; PROLACTIN; DRD2 PROTEIN, HUMAN;

ARTICLE; CLINICAL EFFECTIVENESS; DOPAMINE D2 RECEPTOR GENE; DRUG EFFICACY; DRUG RESPONSE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIATION; GENOTYPE; HUMAN; HYPERPROLACTINEMIA; META ANALYSIS; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SCHIZOPHRENIA; SEX DIFFERENCE; SYSTEMATIC REVIEW; DRUG EFFECTS; GENETICS; METABOLISM; PSYCHOSIS;

ANTIPSYCHOTIC AGENTS; HUMANS; PROLACTIN; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 84974850994     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2016.06.002     Document Type: Article

References (53)

1. Aklillu E., Kalow W., Endrenyi L., Harper P., Miura J., Ozdemir V. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet. Genom. 2007, 17:989-993.
2. Alenius M., Wadelius M., Dahl M.L., Hartvig P., Lindström L., Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J. Psychiatr. Res. 2008, 42:884-893.
3. Anderson G.M., Scahill L., McCracken J.T., McDougle C.J., Aman M.G., Tierney E., Arnold L.E., Martin A., Katsovich L., Posey D.J., Shah B., Vitiello B. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol. Psychiatry 2007, 61:545-550.
4. Arinami T., Gao M., Hamaguchi H., Toru M. A functional polymorphism in the promoter region of the dopamine receptor gene is associated with schizophrenia. Hum. Mol. Genet. 1997, 6:577-582.
5. Bakker P.R., van Harten P.N., van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol. Psychiatry 2008, 13:544-556.
6. Borenstein, M., Hedges, L., Higgins, J., Rothstein, H. (Eds), 2005. Comprehensive Meta-analysis. 2. Biostat, New Jersey.
7. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 2002, 302:381-389.
8. Bushe C., Shaw M. Prevalence of hyperprolactinemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J. Psychopharmacol. 2007, 21:768-773.
9. Cabaleiro T., López-Rodríguez R., Ochoa D., Román M., Novalbos J., Abad-Santos F. Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Hum. Psychopharmacol. 2013, 28:205-214.
10. Calarge C.A., Ellingrod V.L., Acion L., Miller D.D., Moline J., Tansey M.J., Schlechte J.A. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet. Genom. 2009, 19:373-382.
11. Correia C.T., Almeida J.P., Santos P.E., Sequeira A.F., Marques C.E., Miguel T.S., Abreu R.L., Oliveira G.G., Vicente A.M. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J. 2010, 10:418-430.
12. De Hert M., Detraux J., Peuskens J. Second-generation and newly approved antipsychotics: serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opin. Drug Saf. 2014, 13:605-624.
13. De Hert M., Peuskens J., Sabbe T., Mitchell A.J., Stubbs B., Neven P., Wildiers H., Detraux J. Relationship between prolactin, breast cancer risk and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr. Scand. 2015, (Epubaheadofprint). 10.1111/acps.12459.
14. Duval S., Tweedie R. A nonparametric trim and fill method of accounting for publication bias in meta-analysis. J. Am. Stat. Assoc. 2000, 95:89-98.
15. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
16. Fraguas D., Correll C.U., Merchán-Naranjo J., Rapado-Castro M., Parellada M., Moreno C., Arango C. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur. Neuropsychopharmacol. 2011, 21:621-645.
17. Güzey C., Scordo M.G., Spina E., Landsem V.M., Spigset O. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur. J. Clin. Pharmacol. 2007, 63:233-241.
18. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64:2291-2314.
19. Houston J.P., Fijal B., Heinloth A.N., Adams D.H. Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients. Psychiatry Res. 2010, 175:171-172.
20. Houston J., Dharia S., Bishop J.R., Ellingrod V.L., Fijal B., Jacobson J.G., Hoffmann V.P. Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry Res. 2011, 187:74-79.
21. Ikeda M., Yamanouchi Y., Kinoshita Y., Kitajima T., Yoshimura R., Hashimoto S., O'Donovan M.C., Nakamura J., Ozaki N., Iwata N. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008, 9:1437-1443.
22. Jönsson E.G., Nöthen M.M., Grünhage F., Farde L., Nakashima Y., Propping P., Sedvall G.C. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 1999, 4:290-296.
23. Kinon B.J., Gilmore J.A., Liu H., Halbreich U.M. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003, 28(Suppl. 2):55-68.
24. Kishimoto T., De Hert M., Carlson H., Manu P., Correll C.U. Osteoporosis and fracture risk in people with schizophrenia. Curr. Opin. Psychiatry 2012, 25:415-429.
25. Kwon J.S., Kim E., Kang D.H., Choi J.S., Yu K.S., Jang I.J., Shin S.G. APLUS study group.,. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur. Neuropsychopharmacol. 2008, 18:897-907.
26. López-Rodríguez R., Román M., Novalbos J., Pelegrina M.L., Ochoa D., Abad-Santos F. DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J. Clin. Psychopharmacol. 2011, 31:555-562.
27. Lencz T., Robinson D.G., Xu K., Ekholm J., Sevy S., Gunduz-Bruce H., Woerner M.G., Kane J.M., Goldman D., Malhotra A.K. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am. J. Psychiatry 2006, 163:529-531.
28. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lässig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382:951-962.
29. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
30. Madhusoodanan S., Parida S., Jimenez C. Hyperprolactinemia associated with psychotropics-a review. Hum. Psychopharmacol 2010, 25:281-297.
31. Mihara K., Kondo T., Suzuki A., Yasui N., Nagashima U., Ono S., Otani K., Kaneko S. Prolactin response to nemonapride a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene. Psychopharmacology (Berl.) 2000, 149:246-250.
32. Mihara K., Suzuki A., Kondo T., Yasui-Furukori N., Ono S., Otani K., Kaneko S., Inoue Y. Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am. J. Med. Genet 2001, 105:271-274.
33. Miura I., Takeuchi S., Katsumi A., Mori A., Kanno K., Yang Q., Mashiko H., Numata Y., Niwa S. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. J. Clin. Psychopharmacol. 2012, 32:106-109.
34. Miura I., Kanno-Nozaki K., Hino M., Horikoshi S., Ota T., Mashiko H., Niwa S., Yabe H. Influence of -141C Ins/Del polymorphism in DRD2 gene on clinical symptoms and plasma homovanillic acid levels in the treatment of schizophrenia with aripiprazole. J. Clin. Psychopharmacol. 2015, 35:333-334.
35. Montgomery J., Winterbottom E., Jessani M., Kohegyl E., Fulmer J., Seamonds B., Josiassen R.C. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J. Clin. Psychiatry 2004, 65:1491-1498.
36. Nagai G., Mihara K., Nakamura A., Suzuki T., Nemoto K., Kagawa S., Ohta I., Arakaki H., Kondo T. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry Clin. Neurosci. 2012, 66:518-524.
37. Neville M.J., Johnstone E.C., Walton R.T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23. 1. Hum. Mutat. 2004, 23:540-545.
38. Noble E.P., Blum K., Ritchie T., Montgomery A., Sheridan P.J. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch. Gen. Psychiatry 1991, 48:648-654.
39. Peuskens J., Pani L., Detraux J., De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014, 28:421-453.
40. Pohjalainen T., Rinne J.O., Någren K., Lehikoinen P., Anttila K., Syvälahti E.K., Hietala J. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 1998, 3:256-260.
41. Pohjalainen T., Någren K., Syvälahti E.K., Hietala J. The dopamine D2 receptor 5'-flanking variant, -141C Ins/Del, is not associated with reduced dopamine D2 receptor density in vivo. Pharmacogenetics 1999, 9:505-509.
42. Roke Y., van Harten P.N., Franke B., Galesloot T.E., Boot A.M., Buitelaar J.K. The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. Pharmacogenet. Genom. 2013, 23:487-493.
43. Schooler N., Rabinowitz J., Davidson M., Emsley R., Harvey P.D., Kopala L., McGorry P.D., Van Hove I., Eerdekens M., Swyzen W., De Smedt G. Early Psychosis Global Working Group.,. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry 2005, 162:947-953.
44. Suzuki A., Mihara K., Kondo T., Tanaka O., Nagashima U., Otani K., Kaneko S. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 2000, 10:335-341.
45. Suzuki Y., Ono S., Sugai T., Fukui N., Watanabe J., Tsuneyama N., Sawamura K., Someya T. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia. Hum. Psychopharmacol. 2011, 26:440-443.
46. Suzuki Y., Sugai T., Fukui N., Watanabe J., Ono S., Tsuneyama N., Saito M., Someya T. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics. Schizophr. Res. 2013, 145:116-119.
47. Thompson J., Thomas N., Singleton A., Piggott M., Lloyd S., Perry E.K., Morris C.M., Perry R.H., Ferrier I.N., Court J.A. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997, 7:479-484.
48. Yasui-Furukori N., Saito M., Tsuchimine S., Nakagami T., Sato Y., Sugawara N., Kaneko S. Association between dopamine-related polymorphisms and plasma concentrations of prolactinduring risperidone treatment in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1491-1495.
49. Young R.M., Lawford B.R., Barnes M., Burton S.C., Ritchie T., Ward W.K., Noble E.P. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br. J. Psychiatry 2004, 185:147-151.
50. Zai C.C., De Luca V., Hwang R.W., Voineskos A., Müller D.J., Remington G., Kennedy J.L. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol. Psychiatry 2007, 12:794-795.
51. Zhang J.P., Lencz T., Malhotra A.K. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am. J. Psychiatry 2010, 167:763-772.
52. Zhang X.R., Zhang Z.J., Zhu R.X., Yuan Y.G., Jenkins T.A., Reynolds G.P. Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics 2011, 12:1127-1136.
53. Zivković M., Mihaljević-Peles A., Bozina N., Sagud M., Nikolac-Perkovic M., Vuksan-Cusa B., Muck-Seler D. The association study of polymorphisms in DAT, DRD2, and COMT genes and acuteextrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. J. Clin. Psychopharmacol. 2013, 33:593-599.